Next-generation neurointerventional medical device innovator MIVI Neuroscience has announced that Waleed Brinjikji (Mayo Clinic, Rochester, USA) has joined the company as its medical director.
“The MIVI team shares my passion for improving the lives of patients who suffer an acute ischaemic stroke,” said Brinjikji. “I am looking forward to representing MIVI in the neurointerventional community and contributing to the advancement of novel technologies that advance stroke treatment.”
As per a company press release, Brinjikji is an internationally respected interventional neuroradiologist who is extensively involved in stroke and neuroendovascular research, with more than 500 peer-reviewed papers and multiple industry and National Institutes of Health (NIH) grants, including for a study on improving revascularisation techniques in stroke.
Most recently, Brinjikji was chief medical officer of Marblehead Medical. He trained at top North American institutions including the University of Toronto (Toronto, Canada) and the Mayo Clinic.
As medical director, Brinjikji will provide MIVI with input and medical guidance across a wide spectrum of its activities, including original clinical research and studies, product design and development, and clinical and customer communications, the release adds.
“We are looking forward to Dr Brinjikji joining our team at this exciting time,” said Bob Colloton, MIVI CEO. “His insights and experience will be invaluable as we continue to achieve our clinical and commercial milestones for our flagship products the Q aspiration catheter and Daise thrombectomy device, and identify new business and development opportunities.”
The Q aspiration catheter delivers “unprecedented aspiration power” by optimising luminal radius and length, the release also notes. It is CE-marked in Europe and under Investigational Device Exemption (IDE) in the USA—where it is currently commercially available for distal access. The Daise thrombectomy device is designed to reduce distal embolisation and improve patient outcomes. It is currently available for investigational use only.
